Serum androgens and gonadotrophins in bronchial carcinoma  by Taggart, D.P. et al.
Respiratory Medicine (1993) 87,455-460 
Serum androgens and gonadotrophins in bronchial s 
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D.P. TAGGART*§,~. E. GRAY?, A. BOWMANS, A. FAICHNEY*ANDK.G.DAVIDSON* 
Departments of Tardiothoracic Surgery and j’Steroid Biochemistry, Royal Infirmary, Glasgow and 
SDepartment of Statistics, Glasgow University, Glasgow, U.K. 
The concentrations of testosterone, free testosterone index derived by two independent techniques (FTIl, FTI2), 
dehydroepiandrosterone sulphate (DHAS), androstenedione (AND), luteinizing hormone (LH), follicle 
stimulating hormone (FSH), and sex hormone binding globulin (SHBG) were measured in 38 healthy male 
controls aged between 40 and 60 years (Group 1) and in 52 male patients with bronchial carcinoma of whom 28 
were aged between 40 and 60 years (Group 2) and 24 were aged over 60 years (Group 3). Compared with Group 1, 
testosterone, FTIl, FTU, and DHAS were significantly lower (P<O.OOl), AND and LH were significantly 
higher (PC 0.001) and there was no significant difference in FSH or SHBG, in Group 2. No significant difference 
between Groups 2 and 3 was found for any variable. Analysis of covariance for Groups 2 and 3 combined, 
showed testosterone, FTI 1 and FT12 were significantly lower in the presence of metastases. These results suggest 
a more widespread abnormality of androgen metabolism in male patients with bronchial carcinoma than a 
simple reduction in serum testosterone; DHAS is also significantly reduced while AND is significantly increased. 
The primary abnormality appears to be at testicular and/or adrenal level as pituitary function appears normal as 
witnessed by compensatory increases in LH. 
Introduction 
The aetiology of low serum testosterone con- 
centrations in male patients with bronchial carcinoma 
(l-3), and in particular its relationship to other 
adrenal androgens, gonadotrophins and its carrier 
protein, is not clearly defined. We therefore examined 
the relationship of serum testosterone and a free 
testosterone index, calculated by two independent 
techniques (FTIl, FT12) to the adrenal androgens 
dehydroepiandrosterone (DHAS) and androstene- 
dione (AND), to hypothalamic-pituitary-testicular 
(HPT) axis function as evidenced by serum concen- 
trations of luteinizing hormone (LH) and follicle- 
stimulating hormone (FSH) and to the carrier protein 
sex-hormone-binding globulin (SHBG). The study 
comprised 38 healthy males aged 40-60 years and 
52 male patients with histologically proven bronchial 
carcinoma. For the sake of comparison and to 
elucidate the effects of increasing age on serum 
testosterone, its intermediary androgen metabolites 
and the function of the HPT axis, the cancer patients 
were divided into those aged 40-60 years and those 
aged over 60 years. 
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Methods 
The concentrations of testosterone, DHAS, AND, 
LH, FSH and SHBG were measured and a free tes- 
tosterone index, calculated by two techniques 
(FTIl, FTQ), were obtained in 38 healthy male 
controls aged 40-60 years (Group 1). The same 
measurements were performed in 52 male patients 
with histologically proven bronchial carcinoma 
divided into two groups according to age: 28 patients 
aged 40-60 years (Group 2) and 24 patients aged over 
60 years (Group 3). 
Data from the cancer patients were analysed 
according to whether the tumour was apparently 
localized (no clinical evidence of extra-thoracic 
disease, full blood count, urea and electrolytes and 
liver function tests normal, complete excision of the 
malignancy, absence of macroscropic intrathoracic 
spread at surgery) and mediastinal node status i.e. Nl 
or N2 disease, 
BIOCHEMICAL ANALYSES 
All blood samples were withdrawn between 0800h 
and lOOOh and serum stored at - 20°C for subsequent 
analyses. 
Testosterone and AND were measured in extracts of 
serum. The radioimmunoassay (RIA) of testosterone 
used an 1251 tracer, an antiserum raised against 
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testosterone-3-0-carboxymethyloxime-BSA (Bio- 
clinical Services Ltd, Cardiff, U.K.) and double 
antibody serum (SAPU reagents, Law Hospital, 
Lanarkshire, U.K.). Intra- and inter-assay coefficients 
of variation (CV) were 8% and 12%. 
The RIA of AND used a [l,2,6,7-3H] label 
(Amersham TRK454), an antiserum raised against 
AND-carboxymethlioether-ovalbumin (Guilday Anti- 
sera Ltd) and double antibody separation. Within and 
between batch CVs were 8 % and 14%. 
DHAS was assayed in unextracted serum using an 
anti-DHAS serum (Dr B. T. Rudd, Birmingham, 
U.K.), [7-,H] DHAS (New England Nuclear) and 
double antibody separation. Within and between 
batch CVs were 10% and 15%. 
Serum LH and FSH wereestimated by conventional 
double antibody RIA. LH was standardized against 
the first International Reference Preparation (IRP) 
(code 68/40); the intra- and inter-assay CVs were 
7% and lo%, respectively. FSH was standardized 
against the second IRP (Code 78/549) and intra- and 
inter-assay CVs were 8% and 12%. 
SHBG capacity was measured by a competitive 
binding technique (4). The intra-assay CV for SHBG 
was 5% and the inter-batch variation 9%. 
A derived free testosterone index was calculated by 
two independent techniques. FTIl was based on the 
technique described by Iqbal and colleagues (5) and 
FTI2 on the technique described by Nanjee and 
Wheeler (6). 
STATISTICAL ANALYSES 
Statistical analysis was performed using the Minitab 
computing package. Some values of endocrine 
metabolites were missing in a few patients and in all 
tables or analyses affected by this the appropriate 
small number of patients was omitted. 
Since the ages in the control and carcinoma groups 
overlapped only in the age range 40-60 years the 
groups were split accordingly. Summary statistics of 
metabolites for the three groups are presented in 
Table 1. As the data were not normally distributed 
the prediction intervals for each metabolite were 
calculated on log scales and then transferred back 
to the original scales. The effect of age on each 
endocrine metabolite for all patient groups was 
assessed by fitting linear regressions over the available 
ages. 
Before comparing data for the Control (Group 1) 
and Carcinoma Groups (Group 2) over the age range 
40-60 years, tests were made of the regression effects of 
age within this restricted age band. Slight increases 
with age (P < 0.04) were detected for LH and SHBG in 
the control group. For these two variables analysis of 
covariance was used to compare Group 1 and 2 with 
age as a covariate. This allows the effect of disease to be 
assessed while controlling for any possible effect of age 
within the 40-60 years age range. In all other cases a 
Student’s t-test was used. t-tests were also used to 
compare the hormone values in carcinoma patients 
where metastases were subsequently detected and in 
those where no evidence of metastases was found. 
In order to illustrate and quantify the degree 
of separation between the Control (40-60 years) 
and Carcinoma (4&60 years) groups, discriminant 
analysis was applied to the various metabolites. 
Results 
Results are presented in Tables l-3. Table 1 presents 
summary statistics in the three groups expressed as 
median and 95% confidence intervals. These were 
calculated in log scales and then transferred back to 
the orginal scales. Table 2 gives the 25th, 50th and 75th 
distribution percentiles of the endocrine metabolites in 
the three groups to allow comparison with previously 
published data. A comparison of Groups 1 and 2 
allows identification of differences between the 
Control and Carcinoma groups over the comparable 
age range 4&60 years, while comparison of Groups 2 
and 3 permits exploration of age-related effects in the 
Cancer groups. 
There were 52 patients with histologically proven 
bronchial malignancies (37 squamous, 6 adenocarci- 
nomas, 6 large-cell and 3 small-cell carcinomas). Ofthe 
28 patients in Group 2, 13 had definite mediastinal 
metastases (i.e. N2 disease), six had peribronchial 
or homolateral nodes (i.e. Nl disease) and nine had 
suspected but not histologically proven mediastinal 
nodes (i.e. NX disease). Of the 24 patients in Group 3, 
12 had N2 disease, ten had Nl disease, and two had 
NX disease (Table 3). 
Testosterone and the free testerone indices (FTIl 
and FT12) and DHAS were significantly lower 
(P-cO.001) in the cancer groups compared to the 
control group. In contrast, AND and LH were signifi- 
cantly higher in the cancer groups (P<O.OOl) while 
there was no significant difference in FSH or SHBG in 
the two age-matched groups. Discriminant analyses 
showed that Groups 1 and 2 could be substantially 
separated by most metabolites except FSH and 
SHBG: the P-values of the respective t-tests were 
testosterone (P=O.OOl), FTIl (P=O.OOl), FT12 
(P<O.OOl), AND (P<O.OOl), DHAS (P<O.OOl), 
LH (P<O.OOl, FSH (P<O.92), SHBG (P=O.53). 
Discriminant analysis by LH and AND for Groups 1 
and 2 is shown in Fig. 1. 
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Table 1 Median and 95% predictive intervals for each variable in the three groups. Normal reference range provided in 
parenthesis 
Control 
Group 1 Group 2 
Cancer 
Group 3 
Numbers 
Age range (years) 
Age mean (years) 
Testosterone (1 l-36 nmol 1-l) 
FTIl (pmol ll’) 
FT12 (pmol 1-l) 
DHAS (2-9 pmol l- ‘) 
Androstenedione (2-l 1 nmol 1-l) 
LH(2-8Ul-‘) 
FSH (2-8 U 1-l) 
SHBG (645 nmol 1-l) 
38 
4&60 
15.8 (s489-26.9) 
541 (295-928) 
394 (251-O) 
3.8 (1.2-14.2) 
3.0 (1.74.8) 
3.3 (1.2-9.6) 
4.8 (2.4-l 1.0) 
29 (15-55) 
28 
40-60 
12 (2?34.9)* 
354 (95-1078)* 
293 (76749)’ 
2.6 (0.684)’ 
5.7 (2.515.1)* 
6.3 (2.1-25.3)* 
4.1 (0.9-29.1)” 
31 (l&76)“5 
24 
>60 
65 
11.1 (2.340.0) 
300 (641082) 
271 (59-883) 
1.8 (0.65.3) 
4.8 (2.7-9.3) 
6.7 (2617.2) 
6.0 (14-23.9) 
38 (15-92) 
* = P < 0.001, NS = non significant for Group 2 vs. Group 1. No significant differences for Group 2 VS. Group 3. 
Table 2 Median and quartiles for each variable in the three groups 
Control 
Group 1 Group 2 
Cancer 
Group 3 
Numbers 
Percentiles 
Age (years) 
Testosterone (1 l-36 nmol ll’) 
FTIl (pm01 ll’ 
FTI2 (pmol I- ‘) 
DHAS (2-9 pmol l- ‘) 
Androstenedione (2-l 1 nmol 1-l) 
LH(2-8Ul-‘) 
25th 
42.8 
12.9 
431 
350 
3.2 
2.5 
2.2 
38 
50th 
46.0 
15.8 
541 
394 
3.8 
3.0 
3.3 
75th 25th 
54.0 48.3 
18.2 7.6 
640 228 
483 166 
5.2 1.0 
3.2 4.3 
5.0 5.0 
28 
50th 
57.0 
12.0 
354 
293 
2.6 
5.7 
6.3 
75th 25th 
58.0 62.3 
14.0 6.5 
423 197 
357 166 
3.7 1.0 
9.0 4.1 
11.3 4.7 
24 
50th 
65.0 
11.1 
300 
271 
1.8 
4.8 
6.7 
75th 
66.8 
14.9 
405 
352 
2.6 
6.3 
9.2 
FSH (2-8 U 1-l) 4.0 4.8 6.8 3.0 4.1 8.1 3.4 6.0 8.6 
SHBG (645 nmoll-‘) 23 29 38 20 31 38 28 38 45 
Table 3 Median of each variable in the cancer groups according to nodal disease 
Nodal status 
Group 2 Group 3 
Nl N2 Nl N2 
Numbers 
Age (years) 
Testosterone (1 l-36 nmolll’) 
FTIl (pm01 1-l) 
FIT2 (pm01 1-l) 
DHAS (2-9 pm01 1 - ‘) 
Androstenedione (2-11 nmol lm 
LH(2-8Ull’ 
FSH (2-8 U 1-l) 
SHBG (645 nmol 1-l) 
6 13 10 12 
51 56 65 65 
14 9.8* 14 7.6t 
421 338 371 2w 
356 180 345 201-l 
3.4 2.2 2.6 1.4 
4.9 6.3 4.8 4.6 
7.1 7.4 5.5 6.7 
4.1 5.1 6.6 4.8 
28 23 38 33 
*P=O.O57 for testosterone in Group 2; tP=O.Ol for testosterone, FTIl and FTI2 in 
Group 3. 
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Fig. I Discriminant analysis of Group 1 and 2 using log LH and androstenedine. 
There was no convincing difference between Groups 
2 and 3 for any variable. Analysis of the carcinoma 
groups with reference to the histologically proven 
presence or absence of mediastinal node involvement 
(i.e. N2 or Nl disease) is summarized in Table 3. 
No significant differences, except a marginal one for 
testosterone (P = 0.057) were identified within Group 
2. In contrast, significant differences were identified in 
Group 3, between N2 and Nl disease, for the variables 
testosterone FTIl and FT12. There was some evidence 
that testosterone decreases with age and so the 
importance of these variables was confirmed by 
carrying out a more powerful analysis of covariance on 
Groups 2 and 3 combined: testosterone, FTIl and 
FT12 were significantly lower (P~0.01) in patients 
with N2 disease in both Groups 2 and 3 using age as a 
covariate. 
Discussion 
The aetiology of low serum testosterone con- 
centrations in male patients with bronchial carcinoma 
(l-3) is uncertain. In particular, its relationship to 
other adrenal androgens such as DHAS and AND, to 
the gonadotrophins LH and FSH and to its carrier 
protein SHBG has not been clearly elucidated. 
Furthermore, interpretation of serum hormone 
levels in male patients with bronchial carcinoma is 
complicated by the effects of increasing age. There is an 
age-related decline in androgen concentration, most 
significantly after 70 years of age (7), while FSH con- 
centrations increase with age and LH concentrations 
appear to be independent of age (8). Finally, low serum 
testosterone concentrations have been reported in a 
variety of non-malignant illnesses (9-l 1) suggesting 
that chronic ill-health may itself influence androgen 
metabolism. 
In the current study the cancer patients were divided 
into those aged between 40-60 years and those greater 
than 60 years to separate the effects of ageing and 
malignancy on the serum concentrations of androgens 
and gonadotrophins. In our control group regression 
analysis showed a slight effect of age on LH and SHBG 
levels only and for these two variables analysis of 
covariance was used to compare Groups 1 and 2 with 
age as a covariate. Within the cancer groups regression 
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analysis did not show any significant effect of 
increasing age on the serum concentration of any 
metabolite. 
The current study confirms the presence of lower 
serum testosterone concentrations in male patients 
with bronchial carcinoma and our previous finding 
that a low serum testosterone concentration is more 
likely in patients with metastatic disease (1). In the 
current study serum testosterone (FTIl and FT12 were 
lower in patients with N2 disease in both cancer groups 
although this was statistically significant only in 
Group 3 (probably because of the small number of 
patients with Nl disease in Group 2). 
The reductions in FTIl and FT12 in the cancer 
patients suggest that the predominant abnormality 
of testosterone metabolism in malignancy and, 
particularly, in those with metastases, is a reduction 
in the free, physiologically active, component. After 
testicular secretion testosterone is mainly bound to 
SHBG and, to a lesser extent, albumin. Williams and 
colleagues reported that low androgen concentrations 
in patients with bronchial carcinoma was predomi- 
nantly due to elevated levels of SHBG (3) but in 
our study there was no difference in SHBG concen- 
tration between the control patients and those with 
carcinoma. 
A low testosterone concentration in male patients 
with bronchial carcinoma could be a consequence of 
reduced testicular production of testosterone or, 
alternatively, increased utilization by the tumour. Low 
serum testosterone concentrations in patients with 
pancreatic carcinoma have been attributed to the 
presence of high activities of sex-steroid biosynthetic 
enzymes, such as aromatase and 5-a-reductase, within 
the tumour which use testosterone as a substrate for 
growth and metabolism (12). To our knowledge this 
possibility has not been explored for bronchial 
carcinoma. 
Whatever the mechanism of a low serum testoster- 
one in malignancy the compensatory response of a 
normal hypothalamic-pituitary-testicular axis should 
be an increase in LH and FSH. If the primary cause 
of a low serum testosterone concentration was 
depression of the hypothalamic-pituitary axis then low 
concentrations of LH and FSH would accompany a 
low serum testosterone. Our study demonstrated a 
significant increase in LH in both cancer groups 
whereas a tendency to increased FSH was only 
observed in the older cancer group. This data is similar 
to the results reported by Blackman and colleagues (8) 
and consistent with the hypothesis that malignant 
disease has a more powerful effect on Leydig cell func- 
tion whereas age has a greater effect on seminiferous 
tubule function. 
Our study also demonstrated differences in adrenal 
androgen concentrations between control and cancer 
groups, with significant increases in AND and signifi- 
cant decreases in DHAS in the cancer patients. We 
know of no previous report examining the relationship 
of testosterone, AND and DHAS in cancer patients 
although normal AND and reduced DHAS concen- 
trations have been reported to accompany reduced 
testosterone concentrations in chronic, non-malignant 
illness (9-l 1). A low DHAS concentration probably 
results from reduced adrenal secretion and not a 
reduction in sulphation from DHA as the latter is 
also decreased in chronic illness (9). Elevated AND 
concentrations in the cancer patients could result 
from increased production or reduced degredation; 
Semple and colleagues reported an elevation in AND 
in acutely ill medical patients but normal levels in 
chronically ill patients (9). Whatever the exact 
mechanism it is possible that both processes may be an 
adaptive response to ensure normal corticosteroid 
levels in illness (10). 
Discriminant analysis showed that the age-matched 
control and cancer patients could be adequately 
separated by most metabolites except SHBG and 
FSH. Excellent discrimination between Groups 1 and 
2 is clearly shown for LH and AND in Fig. 1. There 
was no further increase in discrimination by adding 
other metabolites. 
The similarity of some abnormalities of androgen 
metabolism observed in our study with those reported 
in non-malignant illness raise the possibility that 
altered concentrations of testosterone and its inter- 
mediary metabolites may be due, at least in part, to the 
ill-health that accompanies a tumour load rather than 
to the tumour per se. However, alterations in steroid 
metabolism by neoplastic tissue as suggested for 
pancreatic carcinoma (12) is also possible and merits 
further examination. Even if changes in the serum 
concentrations of these metabolites are not entirely 
specific for the presence of bronchial cancer, the 
possibility that they might be of prognostic signifi- 
cance or be useful in monitoring the response to 
surgery, radiotherapy or chemotherapy deserves 
further exploration. 
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